Revenue → Gross Profit: $9.13BCardiometabolic health → Revenue: $7.51BGross Profit → Operating cost: $5.62BGross Profit → Operating profit: $3.52BMounjaro → Cardiometabolic health: $3.09BOperating profit → Net Profit: $2.97BOperating cost → R&D: $2.71BRevenue → Cost of Revenue: $2.17BOncology → Revenue: $2.16BOperating cost → Marketing, S&A: $2.12BVerzenio → Oncology: $1.33BTrulicity → Cardiometabolic health: $1.25BZepbound → Cardiometabolic health: $1.24BImmunology → Revenue: $1.08BTaltz → Immunology: $0.82BJardiance → Cardiometabolic health: $0.77BHumalog → Cardiometabolic health: $0.63BOperating profit → Taxes: $0.55BOperating cost → Restructuring: $0.43BNeuroscience → Revenue: $0.34BOther oncology → Oncology: $0.30BCyramza → Oncology: $0.25BOlumiant → Immunology: $0.23BHumulin → Cardiometabolic health: $0.22BOther → Revenue: $0.21BOperating cost → Other expense: $0.20BEmgality → Neuroscience: $0.19BBasaglar → Cardiometabolic health: $0.18BErbitux → Oncology: $0.16BOperating cost → Acquired IPR&D: $0.15BOther neuroscience → Neuroscience: $0.15BTyvyt → Oncology: $0.12BOther diabetes → Cardiometabolic health: $0.12BCialis → Other: $0.09BForteo → Other: $0.07BOthers → Other: $0.05BOther immunology → Immunology: $0.03BBaqsimi → Cardiometabolic health: $0.01BRevenue: $11.30BGross Profit: $9.13BOperating profit: $3.52BOperating cost: $5.62BNet Profit: $2.97BTaxes: $0.55BCost of Revenue: $2.17BMarketing, S&A: $2.12BAcquired IPR&D: $0.15BR&D: $2.71BRestructuring: $0.43BOther expense: $0.20BMounjaro: $3.09BCardiometabolic health: $7.51BTrulicity: $1.25BJardiance: $0.77BHumalog: $0.63BZepbound: $1.24BHumulin: $0.22BBasaglar: $0.18BBaqsimi: $0.01BOther diabetes: $0.12BVerzenio: $1.33BOncology: $2.16BCyramza: $0.25BErbitux: $0.16BTyvyt: $0.12BOther oncology: $0.30BTaltz: $0.82BImmunology: $1.08BOlumiant: $0.23BOther immunology: $0.03BEmgality: $0.19BNeuroscience: $0.34BOther neuroscience: $0.15BCialis: $0.09BOther: $0.21BForteo: $0.07BOthers: $0.05Bcreated with SankeyArt.comRevenue$11.30B36% Y/YGross Profit$9.13B40% Y/YOperating profit$3.52B68% Y/YOperating cost$5.62B27% Y/YNet Profit$2.97B68% Y/YTaxes$0.55B69% Y/YCost of Revenue$2.17B20% Y/YMarketing, S&A$2.12BAcquired IPR&D$0.15BR&D$2.71BRestructuring$0.43BOther expense$0.20BMounjaro$3.09BCardiometabolic health$7.51B50% Y/YTrulicity$1.25BJardiance$0.77BHumalog$0.63BZepbound$1.24BHumulin$0.22BBasaglar$0.18BBaqsimi$0.01BOther diabetes$0.12BVerzenio$1.33BOncology$2.16B29% Y/YCyramza$0.25BErbitux$0.16BTyvyt$0.12BOther oncology$0.30BTaltz$0.82BImmunology$1.08B17% Y/YOlumiant$0.23BOther immunology$0.03BEmgality$0.19BNeuroscience$0.34B-12% Y/YOther neuroscience$0.15BCialis$0.09BOther$0.21B-34% Y/YForteo$0.07BOthers$0.05BEli Lilly Q2 FY24 Income Statement
2024
Q1 Q2 Q3
Copy and edit diagram